Strategies for Enhancement of Live-Attenuated Salmonella-Based Carrier Vaccine Immunogenicity
Open Access
Abstract
The use of live-attenuated bacterial vaccines as carriers for the mucosal delivery of foreign antigens to stimulate the mucosal immune system was first proposed over three decades ago. This novel strategy aimed to induce immunity against at least two distinct pathogens using a single bivalent carrier vaccine. It was first tested using a live-attenuated Salmonella enterica serovar Typhi strain in clinical trials in 1984, with excellent humoral immune responses against the carrier strain but only modest responses elicited against the foreign antigen. Since then, clinical trials with additional Salmonella-based carrier vaccines have been conducted. As with the original trial, only modest foreign antigen-specific immunity was achieved in most cases, despite the incorporation of incremental improvements in antigen expression technologies and carrier design over the years. In this review, we will attempt to deconstruct carrier vaccine immunogenicity in humans by examining the basis of bacterial immunity in the human gastrointestinal tract and how the gut detects and responds to pathogens versus benign commensal organisms. Carrier vaccine design will then be explored to determine the feasibility of retaining as many characteristics of a pathogen as possible to elicit robust carrier and foreign antigen-specific immunity, while avoiding over-stimulation of unacceptably reactogenic inflammatory responses.Keywords
Funding Information
- National Institutes of Health (1R01AI095309-01A1 and 1R56AI125388-01A1, 1R01AI095309-01A1 and 1R56AI125388-01A1)
This publication has 127 references indexed in Scilit:
- Detection of prokaryotic mRNA signifies microbial viability and promotes immunityNature, 2011
- Programming the magnitude and persistence of antibody responses with innate immunityNature, 2011
- Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccineBMC Biology, 2010
- Mucosal Immunization with AttenuatedSalmonella entericaSerovar Typhi Expressing Protective Antigen of Anthrax Toxin (PA83) Primes Monkeys for Accelerated Serum Antibody Responses to Parenteral PA83 VaccineThe Journal of Infectious Diseases, 2009
- Enhanced Immunity toPlasmodium falciparumCircumsporozoite Protein (PfCSP) by UsingSalmonella entericaSerovar Typhi Expressing PfCSP and a PfCSP-Encoding DNA Vaccine in a Heterologous Prime-Boost StrategyInfection and Immunity, 2007
- Ability of SPI2 mutant of S. typhi to effectively induce antibody responses to the mucosal antigen enterotoxigenic E. coli heat labile toxin B subunit after oral delivery to humansVaccine, 2007
- Phosphoinositide-Mediated Adaptor Recruitment Controls Toll-like Receptor SignalingCell, 2006
- Metabolic load and heterologous gene expressionBiotechnology Advances, 1995
- Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian childrenThe Lancet, 1992
- High-level expression of recombinant genes in Escherichia coli is dependent on the availability of the dnaY gene productGene, 1989